Gyre Therapeutics Inc.
NASDAQ: GYRE · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-04-30
Gyre Therapeutics Inc. (GYRE) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for GYRE.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
GYRE historical valuation range
Where current P/E sits in GYRE's own 5Y range.
GYRE intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Standard discounted cash flow models produce unreliable output for unprofitable or near-breakeven companies. Revenue-based multiples such as P/S and EV/Sales, combined with the historical valuation position above, give a more reliable read for this stock.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
GYRE valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 381.50x
P/S Ratio — History
Current: 5.98x
Is GYRE overvalued in 2026?
Gyre Therapeutics Inc. (GYRE) currently trades at $7.68 per share with a market capitalization of $696,726,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 39/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 381.5x, above its 5-year median of 0.7x.
Looking at its own history, GYRE is currently trading more expensive than 100% of the last 5Y on P/E. This places it in the 100th percentile of its historical range, a zone where forward returns have typically been muted.
A standard DCF model does not produce reliable output for GYRE under current conditions. For unprofitable or near-breakeven companies, revenue-based multiples such as EV/Sales and historical P/S percentile are more informative than intrinsic value calculations.
Financial quality is a concern. The Piotroski F-Score of 0/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: GYRE appears richly valued on our framework, with a Smart Value Score of 39/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is GYRE overvalued in 2026?
Based on a Smart Value Score of 39/100, GYRE appears overvalued. Current price exceeds what fundamentals currently justify.
What is GYRE's fair value?
Standard DCF is unreliable for GYRE due to its current profitability profile. Revenue-based approaches such as EV/Sales or historical P/S percentile are more informative for this stock.
What P/E ratio does GYRE trade at?
GYRE trades at a P/E of 381.5x on trailing twelve-month earnings, compared to its 5-year median of 0.7x.
Is GYRE a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 39/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.
How does GYRE's valuation compare to its history?
On P/E, GYRE currently sits in the 100th percentile of its own 5Y range. That is historically expensive relative to where it has traded over the period.
What is GYRE's Smart Value Score?
GYRE's Smart Value Score is 39/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.